Diagnostic value of somatostatin receptor scintigraphy on cardiac sarcoidosis

Diagnostic value of somatostatin receptor scintigraphy on cardiac sarcoidosis - Somatostatin receptor scintigraphy and cardiac sarcoidosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021567

Enrollment

Registered

2016-03-22

Start date

2016-03-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Sarcoidosis

Interventions

Whole-body and cross sectional images will be obtained using a SPECT camera 4 and 24 hours after injection of 111MBq of OctreoScan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Patients who were diagnosed as Cardiac Sarcoidosis of clinical diagnosis or histological diagnosis.

Exclusion criteria

Exclusion criteria: 1 Patients with a history of adverse reactions to OctreoScan 2 Patients taking the medication Octreotide 3 Patients having serious liver diseases 4 Patients having chronic renal failure with a serum creatinine level of 2.0 mg/dL or higher 5 Patients with malignant neoplasms 6 Pregnant or breastfeeding women 7 Patients having difficulty to get cooperation 8 Patients who were considered as unsuitable for this study

Design outcomes

Primary

Measure	Time frame
Detection of myocardial involvement and comparison among imaging modalities in patients with cardiac sarcoidosis	—

Countries

Japan

Contacts

Public ContactToru Awaya

National Center for Global Health and Medicine Department of Cardiology

toru0228@gmail.com03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026